From ze­ro to hero: En­do­cyte’s lit­tle deal a year ago spurred a come­back capped by $2.1B No­var­tis buy­out

A year ago, with its stock in the toi­let af­ter its lead drug flopped in Phase III, forc­ing a re­struc­tur­ing, new En­do­cyte CEO Mike Sher­man said every­thing you would ex­pect a biotech chief to say af­ter com­plet­ing a small li­cens­ing deal for a new lead drug. The $12 mil­lion up­front deal with ABX was trans­for­ma­tion­al, he boast­ed to re­porters. It was a block­buster head­ed to a multi­bil­lion dol­lar mar­ket. 

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER